| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Genetic Oncology and Laboratory of Tumor Biology [F. E., F. K., T. N., D. B., H. S.], Department of Anatomic Pathology [J. J.], and INSERM U 379 [F. E., H. S.], Paoli-Calmettes Institute, 232 Boulevard Sainte Marguerite, Marseille 13009; INSERM U 119, 27 Bd Leï Roure, Marseille 13009 [D. B.]; Unit of Genetic Oncology [D. S-L.] and Department of Anatomic Pathology [A. V-S.], Curie Institute, 75231 Paris Cedex 05; Unit of Genetic Oncology and Anatomic Pathology Service, Bergonié Foundation, 33076 Bordeaux Cedex [M. L.]; and Department of Anatomic Pathology, Léon Bérard Center, 89373 Lyon Cedex 08 [C. B.], France
Histoprognostic grade is a determinant parameter to select the initial therapeutic strategy in breast cancer. Our aim was to analyze the grade repartition in BRCA1-associated breast cancer (BC) and to explore the possible connections between grade and the BRCA1 gene function. We first compared 27 BRCA1-associated BCs from 14 families with 4461 cases from an administrative district registry and 242 cases from a hospital-based registry, matching for grade and constitutive elements, and then considered their repartition in families.
We observed a prevalence of grade 3 (P < 0.0001) in BRCA1-associated BC. This was attributed mainly to nuclear polymorphism (P < 0.0001), mitotic activity (P < 0.0001), and tubular differentiation (P = 0.0004), implying that BRCA1-associated BCs are highly proliferating tumors. Moreover, it is suggested that grade segregates as a genetic trait within families (P = 0.0015), and this was attributed to the mitotic index segregation only (P = 0.0005). Therefore grade, through its components, could be interpreted as the morphological translation of the BRCA1 germ line mutation. Thus, a genotype-phenotype correlation may exist between the type of mutation and the aggressiveness of the disease.
These findings are bound to have an important impact in the care management of hereditary breast cancer at the individual and at the familial level and in the comprehensive approach of breast cancer development.
1 This work was supported by Paoli-Calmettes Institute, INSERM, and grants from La Ligue Nationale Contre le Cancer (the National Office and the district committees of Alpes de Haute Provence, Bouches du Rhône, Corse du Sud, Haute Corse, Var), Caisse Nationale d'Assurance Maladie, CAMPLP, FEGEFLUC, Association pour la Recherche sur le Cancer, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupement de Recherche et d'Etude sur les Génomes.
2 To whom requests for reprints should be addressed. Phone: (33) 91-22-35-40; Fax: (33) 91-22-35-04.
Received 10/17/95. Accepted 12/12/95.
This article has been cited by other articles:
|
|
 |
|
  P van der Groep, P J van Diest, F H Menko, J Bart, E G E de Vries, and E van der Wall Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers J. Clin. Pathol., October 1, 2009; 62(10): 926 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Aaltonen, C. Blomqvist, R.-M. Amini, H. Eerola, K. Aittomaki, P. Heikkila, and H. Nevanlinna Familial Breast Cancers without Mutations in BRCA1 or BRCA2 Have Low Cyclin E and High Cyclin D1 in Contrast to Cancers in BRCA Mutation Carriers Clin. Cancer Res., April 1, 2008; 14(7): 1976 - 1983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Krop, P. Maguire, J. Lahti-Domenici, G. Lodeiro, A. Richardson, H. K. Johannsdottir, H. Nevanlinna, A. Borg, R. Gelman, R. B. Barkardottir, et al. Lack of HIN-1 Methylation in BRCA1-linked and "BRCA1-like" Breast Tumors Cancer Res., May 1, 2003; 63(9): 2024 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Lakhani, M. J. van de Vijver, J. Jacquemier, T. J. Anderson, P. P. Osin, L. McGuffog, and D. F. Easton The Pathology of Familial Breast Cancer: Predictive Value of Immunohistochemical Markers Estrogen Receptor, Progesterone Receptor, HER-2, and p53 in Patients With Mutations in BRCA1 and BRCA2 J. Clin. Oncol., May 1, 2002; 20(9): 2310 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ben David, A. Chetrit, G. Hirsh-Yechezkel, E. Friedman, B.D. Beck, U. Beller, G. Ben-Baruch, A. Fishman, H. Levavi, F. Lubin, et al. Effect of BRCA Mutations on the Length of Survival in Epithelial Ovarian Tumors J. Clin. Oncol., January 15, 2002; 20(2): 463 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S R Lakhani Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer Mol. Pathol., October 1, 2001; 54(5): 281 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S A J Vaziri, R R Tubbs, G Darlington, and G Casey Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers Mol. Pathol., August 1, 2001; 54(4): 259 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. J. Vaziri, L. M. Krumroy, P. Elson, G. T. Budd, G. Darlington, J. Myles, R. R. Tubbs, and G. Casey Breast Tumor Immunophenotype of BRCA1-Mutation Carriers Is Influenced by Age at Diagnosis Clin. Cancer Res., July 1, 2001; 7(7): 1937 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ricevuto, H. Sobol, D. Stoppa-Lyonnet, A. Gulino, P. Marchetti, C. Ficorella, S. Martinotti, T. Meo, and M. Tosi Diagnostic Strategy for Analytical Scanning of BRCA1 Gene by Fluorescence-assisted Mismatch Analysis Using Large, Bifluorescently Labeled Amplicons Clin. Cancer Res., June 1, 2001; 7(6): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.T.M. Brekelmans, C. Seynaeve, C.C.M. Bartels, M.M.A. Tilanus-Linthorst, E.J. Meijers-Heijboer, C.M.G. Crepin, A.N. van Geel, M. Menke, L.C. Verhoog, A. van den Ouweland, et al. Effectiveness of Breast Cancer Surveillance in BRCA1/2 Gene Mutation Carriers and Women With High Familial Risk J. Clin. Oncol., February 15, 2001; 19(4): 924 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ashida, T. Fukutomi, H. Tsuda, S. Akashi-Tanaka, and T. Ushijima Atypical Medullary Carcinoma of the Breast with Cartilaginous Metaplasia in a Patient with a BRCA1 Germline Mutation Jpn. J. Clin. Oncol., December 1, 2000; 30(1): 30 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Verhoog, E. M. J. J. Berns, C. T. M. Brekelmans, C. Seynaeve, E. J. Meijers-Heijboer, and J. G. M. Klijn Prognostic Significance of Germline BRCA2 Mutations in Hereditary Breast Cancer Patients J. Clin. Oncol., November 1, 2000; 18(90001): 119s - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Eisinger, C. Juliain-Reynier, and H. Sobol Re: Biologic Characteristics of Interval and Screen-Detected Breast Cancers J Natl Cancer Inst, September 20, 2000; 92(18): 1533 - 1534. [Full Text] [PDF]
|
|
|
|
|
|
R. Lidereau, F. Eisinger, M.-H. Champème, C. Noguès, I. Bièche, D. Birnbaum, C. Pallud, J. Jacquemier, and H. Sobol Major Improvement in the Efficacy of BRCA1 Mutation Screening Using Morphoclinical Features of Breast Cancer Cancer Res., March 1, 2000; 60(5): 1206 - 1210. [Abstract] [Full Text]
|
|
|
|
|
|
S. R. Lakhani, B. A. Gusterson, J. Jacquemier, J. P. Sloane, T. J. Anderson, M. J. van de Vijver, D. Venter, A. Freeman, A. Antoniou, L. McGuffog, et al. The Pathology of Familial Breast Cancer: Histological Features of Cancers in Families Not Attributable to Mutations in BRCA1 or BRCA2 Clin. Cancer Res., March 1, 2000; 6(3): 782 - 789. [Abstract] [Full Text]
|
|
|
|
|
|
M. Robson, D. Levin, M. Federici, J. Satagopan, F. Bogolminy, A. Heerdt, P. Borgen, B. McCormick, C. Hudis, L. Norton, et al. Breast Conservation Therapy for Invasive Breast Cancer in Ashkenazi Women With BRCA Gene Founder Mutations J Natl Cancer Inst, December 15, 1999; 91(24): 2112 - 2117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-A. Phillips, I. L. Andrulis, and P. J. Goodwin Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different? J. Clin. Oncol., November 1, 1999; 17(11): 3653 - 3663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Eisinger, J. Jacquemier, E. Charafe-Jauffret, M.-C. Rio, D. Birnbaum, and H. Sobol More About: Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations J Natl Cancer Inst, August 18, 1999; 91(16): 1421 - 1422. [Full Text] [PDF]
|
|
|
|
|
|
K. Yoshikawa, K. Honda, T. Inamoto, H. Shinohara, A. Yamauchi, K. Suga, T. Okuyama, T. Shimada, H. Kodama, S. Noguchi, et al. Reduction of BRCA1 Protein Expression in Japanese Sporadic Breast Carcinomas and Its Frequent Loss in BRCA1-associated Cases Clin. Cancer Res., June 1, 1999; 5(6): 1249 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Armes, L. Trute, D. White, M. C. Southey, F. Hammet, A. Tesoriero, A.-M. Hutchins, G. S. Dite, M. R. E. McCredie, G. G. Giles, et al. Distinct Molecular Pathogeneses of Early-Onset Breast Cancers in BRCA1 and BRCA2 Mutation Carriers: A Population-based Study Cancer Res., April 1, 1999; 59(8): 2011 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Lee, S. Wacholder, J. P. Struewing, M. McAdams, D. Pee, L. C. Brody, M. A. Tucker, and P. Hartge Survival After Breast Cancer in Ashkenazi Jewish BRCA1 and BRCA2 Mutation Carriers J Natl Cancer Inst, February 3, 1999; 91(3): 259 - 263. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Durocher, J. Simard, J. Ouellette, V. Richard, F. Labrie, and G. Pelletier Localization of BRCA1 Gene Expression in Adult Cynomolgus Monkey Tissues J. Histochem. Cytochem., September 1, 1997; 45(9): 1173 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Schrag, K. M. Kuntz, J. E. Garber, and J. C. Weeks Decision Analysis -- Effects of Prophylactic Mastectomy and Oophorectomy on Life Expectancy among Women with BRCA1 or BRCA2 Mutations N. Engl. J. Med., May 15, 1997; 336(20): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Ludwig, D L Chapman, V E Papaioannou, and A Efstratiadis Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes & Dev., May 15, 1997; 11(10): 1226 - 1241. [Abstract] [PDF]
|
|
|
|
|
|
S. C. Rubin, I. Benjamin, K. Behbakht, H. Takahashi, M. A. Morgan, V. A. LiVolsi, A. Berchuck, M. G. Muto, J. E. Garber, B. L. Weber, et al. Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of BRCA1 N. Engl. J. Med., November 7, 1996; 335(19): 1413 - 1416. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
